Move beyond your current position

Agendia was founded in 2003 by Netherlands Cancer Institute (NKI). The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling to determine tumor specific properties. These in vitro tests offer physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.

InnoTact Consulting is a life sciences specialist and offers clarity in identifying opportunities for success. The InnoTact consultants understand the underlying technology and are well-acquainted with the market. Consequently, they can offer insight into the complex situations its clients face in order to develop effective solutions.

A Leading Global Clinical Research Organization (CRO) Providing Services in All Phases of Clinical Trials

PRA International is one of the world's leading global clinical research organizations, conducting clinical trials in more than 75 countries across six continents. PRA provides outsourced clinical services across all phases of pharmaceutical and biotech drug development. Through its 30+ years of experience, PRA has developed the operational and therapeutic expertise to provide high quality, global service while maintaining our differentiating PERSONAL ELEMENT of commitment to excellence.

Bringing science to life

Danone Research – Centre for Specialised Nutrition is a life sciences innovation centre for the development of new product concepts for Baby Nutrition and Medical Nutrition. We create formulas that provide clinically substantiated health benefits to vulnerable consumers – infants, toddlers, elderly and patients.

Top Institute Pharma is a public-private partnership in which scientific and business worlds work together on a multidisciplinary research aimed at improving the development of socially valuable medicines. Our research portfolio is based on the disease areas as specified in Priority Medicines, a report by the WHO.

The BioMedical Materials program (BMM) is a public-private partnership in which leading industrial and academic players and the Dutch government are united to stimulate groundbreaking research into the development of biomedical materials. BMM aims at enabling medical breakthroughs in healthcare to meet the increasing socio-economic demand for more effective and efficient medical treatment. Moreover, by stimulating biomedical material research, BMM further strengthens the world-leading position of the Netherlands in the field of biomedical materials.

Skyline Diagnostics develops and commercializes diagnostic products and services with a high additive clinical value for patients with cancer. The Profilers are based on gene expression microarray technology (Affymetrix GeneChip®). Skyline Diagnostics products provides the clinician in-depth insight in the clinically relevant subtypes of the diseases, prognosis of individual patients and response to treatment. This information facilitates the treatment decision making process.

Genmab focuses on products to treat various cancers, where human antibodies are expected to be particularly useful as they should lend themselves to long-term therapy without the risk of rejection by the body's immune system. Furthermore, Genmab is evaluating a large number of interesting disease targets for future product development.